269 related articles for article (PubMed ID: 19866475)
1. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.
Qian DZ; Rademacher BL; Pittsenbarger J; Huang CY; Myrthue A; Higano CS; Garzotto M; Nelson PS; Beer TM
Prostate; 2010 Mar; 70(4):433-42. PubMed ID: 19866475
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.
Nomura T; Yamasaki M; Hirai K; Inoue T; Sato R; Matsuura K; Moriyama M; Sato F; Mimata H
Mol Cancer; 2013 Apr; 12():27. PubMed ID: 23566222
[TBL] [Abstract][Full Text] [Related]
3. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.
Geng H; Rademacher BL; Pittsenbarger J; Huang CY; Harvey CT; Lafortune MC; Myrthue A; Garzotto M; Nelson PS; Beer TM; Qian DZ
Cancer Res; 2010 Apr; 70(8):3239-48. PubMed ID: 20388787
[TBL] [Abstract][Full Text] [Related]
4. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.
Desarnaud F; Geck P; Parkin C; Carpinito G; Makarovskiy AN
Cancer Biol Ther; 2011 Jan; 11(2):204-12. PubMed ID: 21057205
[TBL] [Abstract][Full Text] [Related]
6. The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
Natsagdorj A; Izumi K; Hiratsuka K; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Shigehara K; Nakata H; Mizokami A
Anticancer Res; 2023 Jun; 43(6):2561-2569. PubMed ID: 37247914
[TBL] [Abstract][Full Text] [Related]
7. Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells.
Gomez LA; de Las Pozas A; Perez-Stable C
Mol Cancer Ther; 2006 May; 5(5):1216-26. PubMed ID: 16731754
[TBL] [Abstract][Full Text] [Related]
8. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
9. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
[TBL] [Abstract][Full Text] [Related]
10. Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.
Eftekhari S; Montazeri H; Tarighi P
Eur J Pharmacol; 2020 Jul; 878():173102. PubMed ID: 32283060
[TBL] [Abstract][Full Text] [Related]
11. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.
Zhao L; Lee BY; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Kaplan W; Breit SN; Sutherland RL; Henshall SM; Horvath LG
Cancer Res; 2009 Oct; 69(19):7696-703. PubMed ID: 19773444
[TBL] [Abstract][Full Text] [Related]
12. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
Crea F; Duhagon Serrat MA; Hurt EM; Thomas SB; Danesi R; Farrar WL
Int J Cancer; 2011 Apr; 128(8):1946-54. PubMed ID: 20568112
[TBL] [Abstract][Full Text] [Related]
13. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
14. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.
Gao Q; Zheng J
Biomed Pharmacother; 2018 Jan; 97():528-534. PubMed ID: 29091904
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75.
Mediavilla-Varela M; Pacheco FJ; Almaguel F; Perez J; Sahakian E; Daniels TR; Leoh LS; Padilla A; Wall NR; Lilly MB; De Leon M; Casiano CA
Mol Cancer; 2009 Aug; 8():68. PubMed ID: 19715609
[TBL] [Abstract][Full Text] [Related]
16. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.
O'Neill AJ; Prencipe M; Dowling C; Fan Y; Mulrane L; Gallagher WM; O'Connor D; O'Connor R; Devery A; Corcoran C; Rani S; O'Driscoll L; Fitzpatrick JM; Watson RW
Mol Cancer; 2011 Oct; 10():126. PubMed ID: 21982118
[TBL] [Abstract][Full Text] [Related]
17. Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.
Biernacka KM; Persad RA; Bahl A; Gillatt D; Holly JM; Perks CM
Endocr Relat Cancer; 2017 Jan; 24(1):17-30. PubMed ID: 27754854
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells.
Li Y; Hong X; Hussain M; Sarkar SH; Li R; Sarkar FH
Mol Cancer Ther; 2005 Mar; 4(3):389-98. PubMed ID: 15767548
[TBL] [Abstract][Full Text] [Related]
19. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]